AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Dillon & Associates Inc.

Dillon & Associates Inc. grew its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 27.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,850 shares of the company’s stock after buying an additional 7,013 shares during the quarter. Dillon & Associates Inc.’s holdings in AstraZeneca were worth $2,562,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its holdings in AstraZeneca by 17.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after purchasing an additional 9,002,450 shares in the last quarter. Capital World Investors boosted its position in shares of AstraZeneca by 0.3% in the first quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after buying an additional 29,497 shares during the period. Envestnet Asset Management Inc. grew its stake in shares of AstraZeneca by 16.7% in the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock valued at $266,565,000 after buying an additional 488,644 shares in the last quarter. Clearbridge Investments LLC lifted its holdings in AstraZeneca by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock worth $265,458,000 after buying an additional 186,010 shares in the last quarter. Finally, Fayez Sarofim & Co boosted its stake in shares of AstraZeneca by 4.7% during the 1st quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock valued at $202,588,000 after buying an additional 134,784 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AZN. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen increased their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Up 0.6 %

AstraZeneca stock opened at $65.19 on Wednesday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.89. The firm has a market capitalization of $202.13 billion, a P/E ratio of 31.49, a P/E/G ratio of 1.20 and a beta of 0.47. The company has a 50-day simple moving average of $76.20 and a 200-day simple moving average of $78.47.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.